MedTrace Logo

A Study of the Safety and Antiretroviral Activity of 3BNC117

NCT02588586 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-06-16

Study results available
· View outcomes & findings →

Summary

This study evaluates the effects of four infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART, and its safety during a brief analytical interruption of antiretroviral therapy.

Conditions

  • HIV-1 Infection

Interventions

DRUG

3BNC117

3BNC117 infusions

OTHER

Antiretroviral Treatment Interruption

Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Weill Medical College of Cornell University

    collaborator OTHER

  • Montefiore Medical Center

    collaborator OTHER

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Marina Caskey, MD · The Rockefeller University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-02-28
Completion
2018-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02588586 on ClinicalTrials.gov